Formulation Development
SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical-Stage Pharmaceutical Portfolio to Publicly Traded Company
SciSparc Ltd. recently announced it signed a non-binding letter of intent (LOI) to spin off its advanced clinical-stage pharmaceutical portfolio and its equity stake in…
Silo Pharma Announces Exclusive Global License for Lead Candidate
Silo Pharma, Inc. recently announced it has entered into an exclusive, global license agreement with Columbia University to further develop, manufacture, and commercialize its lead…
CureVac Initiates Strategic Restructuring to Align Resources With Focus on High-Value mRNA Pipeline Opportunities
CureVac N.V. recently announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other select areas of substantial unmet…
Medigene AG Expands Patent Portfolio With the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor
Medigene AG recently announced it has been issued a patent by the Chinese Patent Office protecting its T cell receptor (TCR) targeting NY-ESO-1 (New York…
IntelGenx Obtains Preliminary Efficacy Results for the BUENA Montelukast VersaFilm Phase 2a Clinical Trial in Patients With Mild to Moderate Alzheimer’s Disease
IntelGenx Corp. has successfully completed the BUENA Alzheimer’s disease (AD) study. The BUENA study was designed as a Phase 2a proof of concept study to…
Apollomics Announces Updated Strategic Focus & Leadership Team Changes
Apollomics Inc. recently announced an updated strategic focus for the clinical development of vebreltinib by focusing on NSCLC patients with Met Amplification, as well as…
Sobi Initiates Rolling BLA to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout
Sobi recently announced the initiation of a rolling Biologics License Application (BLA) to the USA FDA for SEL-212. The submission is based on the results…
Cellular Origins Acquires ACTIA Platform IP to Enhance Automated Cell Therapy Manufacturing
Cellular Origins recently announced the acquisition of the ACTIA (Autologous Cell Therapy Industrial Automation) Platform IP, developed by Geoff Hodge whilst CEO of SOTIO Biotech…
Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients With Myasthenia Gravis
Cartesian Therapeutics, Inc. recently announced positive topline results from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG). Descartes-08, Cartesian’s lead…
Annovis Bio Announces New Data From Phase 3 Parkinson’s Study
Annovis Bio Inc. recently announced new data from its Phase 3 PD study demonstrating that buntanetap is safe and effective in improving motor and non-motor…
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
Inozyme Pharma, Inc. recently announced the US FDA has granted Fast Track designation to INZ-701 for the treatment of ABCC6 Deficiency. “Through Fast Track designation,…
Alvotech Announces Positive Topline Results for a Proposed Biosimilar for Prolia & Xgeva
Alvotech recently announced positive topline results from a confirmatory patient study for AVT03, a proposed biosimilar to Prolia (denosumab) and Xgeva (denosumab). The study met…
Touchlight & LenioBio Collaborate to Accelerate Development of Protein Therapeutics for Pandemic Response
LenioBio and Touchlight recently announced a supply agreement aimed at leveraging the revolutionary capabilities of Touchlight’s rapid enzymatic doggybone DNA (dbDNA) to achieve unprecedented speed…
Navin Molecular to Invest Up to $35 Million to Expand GMP Manufacturing Capabilities
Navin Molecular recently announced a $35-million investment to construct a 9,000-square-meter GMP manufacturing plant in Dewas, India. The new facility will nearly double overall capacity…
Ovid Therapeutics & Graviton Bioscience Announce Topline Data From Phase 1 Clinical Trial Studying a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
Ovid Therapeutics Inc. and Graviton Bioscience Corporation recently announced the results from their Phase 1 healthy volunteer study evaluating the safety, tolerability, and pharmacokinetic (PK)…
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
Biora Therapeutics, Inc. recently shared positive topline results from its clinical trial of BT-600, an orally administered drug-device combination in development for the potential treatment…
Syncromune Granted FDA Fast-Track Designation for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
Syncromune Inc. recently announced the US FDA has granted Fast Track designation for SYNC-T SV-102 therapy, its lead candidate for the treatment of patients with metastatic…
Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain
Artelo Biosciences, Inc. recently announced Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, presented preclinical data related to ART26.12, Artelo’s novel fatty acid binding…
WEBINAR - Development of Orally Delivered GLP-1 Therapeutics…From Diabetes to Obesity and Beyond
Join Quotient Sciences’ experts on July 18 as we explore the latest developments in orally-delivered GLP-1 agonists, the potential for these therapeutics and overcoming the manufacturing challenges.
NeOnc Technologies Completes $18.5-Million Financing, Advances Phase 2 Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status
NeOnc Technologies Holdings, Inc. has completed an $18.5-million financing to support the ongoing development and Phase 1 and 2 clinical studies of its novel drug…
